ASPIRIN: Neurodevelopmental Follow-up Trial

CompletedOBSERVATIONAL
Enrollment

666

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Neurodevelopmental Abnormality
Interventions
DRUG

Aspirin

Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.

DRUG

Placebo

Participant's mothers were administered placebo throughout their pregnancy with the participant.

Trial Locations (14)

10032

Columbia University, New York

19107

Thomas Jefferson University, Philadelphia

19718

Christiana Care, Newark

27599

University of North Carolina School of Medicine, Chapel Hill

27709

RTI International, Research Triangle Park

35233

University of Alabama, Birmingham, Birmingham

80208

University of Colorado Health Sciences Center, Denver

02115

Boston University, Boston

Unknown

Kinshasa School of Public Health, Kinshasa

INCAP, Guatemala City

Jawaharlal Nehru Medical College, Belagavi

Lata Medical Research Foundation, Nagpur

Aga Khan University, Karachi

University Teaching Hospital, Lusaka

All Listed Sponsors
collaborator

Thomas Jefferson University

OTHER

collaborator

RTI International

OTHER

collaborator

Thrasher Research Fund

OTHER

lead

NICHD Global Network for Women's and Children's Health

NETWORK

NCT04888377 - ASPIRIN: Neurodevelopmental Follow-up Trial | Biotech Hunter | Biotech Hunter